Palisade Strategies, LLC

Palisade Strategies, LLC, a service-disabled veteran-owned small business (SDVOSB) headquartered in Valrico, Florida, delivers pharmacy benefit management, prescription fulfillment, and emergency prescription dispensing services to the Department of Veterans Affairs as a prime contractor exclusively under SDVOSB set-asides and other small-business vehicles. The company is a for-profit limited liability company with veteran-owned and self-certified small disadvantaged business designations; active SBA certifications for both SDVOSB and veteran-owned small business status run through January 2029. Palisade Strategies competes across a portfolio where 100 percent of recent awards are prime contracts—the vendor self-performs all pharmacy services work without subcontractors and carries no sub-award exposure.

Palisade Strategies' capability footprint is narrowly focused on VA pharmacy logistics. The company provides first-fill prescription fulfillment, urgent and emergency prescription dispensing, pharmacy refill services, and pharmacy benefit management across nine regional Veterans Integrated Service Networks (VISNs). Recent representative work includes a $1,450,496 five-year emergency prescription services purchase order with VISN 7 (Dublin, Georgia) awarded July 2023; an $811,040 five-year community pharmacy service purchase order with VISN 7 (Columbia, South Carolina) awarded July 2024; a $1,518,000 BPA call with VISN 22 (Long Beach, California) for first-fill and urgent prescription fulfillment through March 2027; and an $824,240 IDIQ with VISN 15 (Columbia, Missouri) for non-personal pharmacy benefit management through November 2030. The company operates at the intersection of NAICS 456110 (Pharmacies and Drug Retailers) and 511990 (Pharmacy Benefit Management and Other Third Party Administration), and delivers services under PSC Q517 (Pharmacy Services).

Customer concentration is extreme and deliberately so. Five regional VISNs account for 72 percent of awards by count and 84 percent of combined potential value: VISN 22 leads by dollars ($15.6 million across 19 awards), followed by VISN 21 ($13.5 million across 26 awards), VISN 10 ($6.9 million across 30 awards), VISN 16 ($5.1 million across 13 awards), and VISN 15 ($4.9 million across 16 awards). The vendor operates exclusively within the VA; the source lists ten distinct customer agencies served, but nine are regional VISN subdivisions of the Department of Veterans Affairs, with the sole outlier being VA central administration. This customer concentration reflects both the vendor's deliberate positioning as a VA-specialized pharmacy services provider and the structural reality that Palisade Strategies does not compete for pharmacy work outside the federal VA system.

The vendor's parent vehicle footprint consists of single-award IDIQs and BPAs held directly with regional VISNs rather than government-wide acquisition contracts. The top five parent vehicles by task-order volume are a VISN 10 IDIQ (36C25019D0078, 25 task orders, $1.1 million combined potential value), a VISN 21 BPA (36C26221A0021, 18 task orders, $6.6 million), a VISN 23 BPA (36C26320A0019, 7 task orders, $302 thousand), a VISN 10 IDIQ (36C25520D0037, 6 task orders, $1.2 million), and a VISN 16 IDIQ (36C25620D0014, 6 task orders, $1.4 million). All parent vehicles are SDVOSB set-asides or Total Small Business vehicles held as single-award contracts; there are no multi-award GWACs or GSA Schedule positions in the source.

Activity has been moderate and concentrated in the past two years. The vendor received 20 awards in 2022, 18 in 2023, 14 in 2024, 23 in 2025, and 7 through September 2026 (year in progress). Over the next twenty-four months, six awards carrying combined potential value of $4 million face ultimate completion, representing moderate recompete exposure for the vendor and corresponding recompete opportunity for competitors.

Service Contract Inventory data shows Palisade Strategies reported $1.9 million in invoiced revenue across SCI-reportable federal service contracts from FY2022 through FY2025. The annual breakdown reveals $981 thousand in FY2023, $310 thousand in FY2024, and $613 thousand in FY2025, with no SCI-reportable revenue in FY2022. The SCI dataset captured roughly 0.3 to 0.4 FTEs delivered in FY2023–FY2024, with FY2025 showing 0.0 FTEs (a function of reporting lags). On federal services contracts within SCI scope, government-paid rates ranged from a 10th percentile of $145.60 per hour to a median of $798.46 per hour to a 90th percentile of $2,539.74 per hour—a wide spread reflecting the heterogeneity of pharmacy-related task order pricing, from simple prescription-fill work to higher-value emergency or complex benefit management services. Across SCI-reportable prime contracts, Palisade Strategies recorded zero subcontract hours, consistent with the vendor's self-performance model.

The corporate structure includes one named subsidiary, Palisade-Heritage Joint Venture II, LLC, itself an SDVOSB and small business joint venture, suggesting possible teaming arrangements or shared operational capability with Heritage-branded entities. The source offers no detail on this subsidiary's role or shared work.

Palisade Strategies operates as a pure-play VA pharmacy services vendor with no diversification into other federal agencies, sectors, or capability areas. The vendor's competitive posture is defensive against larger national pharmacy networks and offensive within the small-business set-aside space at VISNs where long-term IDIQ and BPA relationships anchor recurring task-order volume. The company has built recurring customer relationships across nine VISNs and holds multiple active single-award vehicles; however, the absence of multi-award IDIQs or GWAC positions limits cross-VISN or inter-agency pipeline flexibility and creates vulnerability to individual VISN recompete losses.

Palisade Strategies is a pharmacy benefit, PPE supplier, and consulting company that works closely with government entities and commercial self-funded businesses to improve patient care and reduce costs. The company leverages best in class technology coupled with a solution based entrepreneurial team to identify health and cost related issues and develop and implement custom-based solutions.